Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCT520FF in Neovascular Age-related Macular Degeneration
NCT06672536Phase 2Recruiting
- Sponsor
- Sinocelltech Group Limited
- Start
- Nov 2024
- Primary completion
- Sep 2026
- Modality
- Fab Fragments
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of SCT-520FF in neovascular age-related macular degeneration (NVAMD) (4 arms), sponsored by Sinocelltech Group Limited. Primary endpoints: Treatment Emergent Adverse Events, Treatment-related Treatment Emergent Adverse Events and 3 more. Started Nov 2024; status: recruiting.
02
Drugs
SCT-520FF
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT06672536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06672536.